Secondary lymphomas of the central nervous system: risk, prophylaxis and treatment

References

• Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte H. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol 2002; 13: 1099–1107
   PubMed Web of Science ®Google Scholar
• Haioun C, Besson C, Lepage E, Theiblemont C, Simon D, Rose C, et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'etudes des lymphomes de l'adulte. Ann Oncol 2000; 11: 685–690
   PubMed Web of Science ®Google Scholar
• Feugier P, Virion J M, Tilly H, Haioun C, Marit G, Macro M, et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol 2004; 15: 129–133
   PubMed Web of Science ®Google Scholar
• Tomita N, Kodama F, Kanamori H, Motomura S, Ishigatsubo Y. Secondary central nervous system lymphoma. Int J Hematol 2006; 84: 128–135
   PubMed Web of Science ®Google Scholar
• Cheung C W, Burton C, Smith P, Linch D C, Hoskin P J, Ardeshna K M. Central nervous system chemoprophylaxis in non-Hodgkin lymphoma: current practice in the UK. Br J Haematol 2005; 131: 193–200
   PubMed Web of Science ®Google Scholar
• Colocci N, Glantz M, Recht L. Prevention and treatment of central nervous system involvement by non-Hodgkin's lymphoma: a review of the literature. Semin Neurol 2004; 24: 395–404
   PubMed Web of Science ®Google Scholar
• Buckstein R, Lim W, Franssen E, Imrie K L. CNS prophylaxis and treatment in non-Hodgkin's lymphoma: variation in practice and lessons from the literature. Leuk Lymphoma 2003; 44: 955–962
   PubMed Web of Science ®Google Scholar
• Doolittle N D, Abrey L E, Shenkier T N, Siegal T, Bromberg J E, Neuwelt E A, et al. Brain parenchyma involvement as isolated central nervous system (CNS) relapse of systemic non-Hodgkin lymphoma: an International primary CNS lymphoma collaborative group report. Blood 2008; 111: 1085–1093
   PubMed Web of Science ®Google Scholar
• Ferrer A, Bosch F, Villamor N, Rozman M, Graus F, Gutiérrez G, et al. Central nervous system involvement in mantle cell lymphoma. Ann Oncol 2008; 19: 135–141
   PubMed Web of Science ®Google Scholar
• Bishop P C, Wilson W H, Pearson D, Janik J, Jaffe E S, Elwood P C. CNS involvement in primary mediastinal large B-cell lymphoma. J Clin Oncol 1999; 17: 2479–2485
   PubMed Web of Science ®Google Scholar
• Salzburg J, Burkhardt B, Zimmermann M, Wachowski O, Woessmann W, Oschlies I, et al. Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster group report. J Clin Oncol 2007; 25: 3915–3922
   PubMed Web of Science ®Google Scholar
• Seidemann K, Tiemann M, Lauterbach I, Mann G, Simonitsch I, Stankewitz K, et al. NHL Berlin-Frankfurt-Münster group. Primary mediastinal large B-cell lymphoma with sclerosis in pediatric and adolescent patients: treatment and results from three therapeutic studies of the Berlin-Frankfurt-Münster group. J Clin Oncol 2003; 21: 1782–1789
   PubMed Web of Science ®Google Scholar
• Zinzani P L, Martelli M, Bertini M, Gianni A M, Devizzi L, Federico M, et al. International extranodal lymphoma study group (IELSG). Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica 2002; 87: 1258–1264
   PubMed Web of Science ®Google Scholar
• Zucca E, Conconi A, Mughal T I, Sarris A H, Seymour J F, Vitolo U, et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the international extranodal lymphoma study group. J Clin Oncol 2003; 21: 20–27
   PubMed Web of Science ®Google Scholar
• Laskin J J, Savage K J, Voss N, Gascoyne R D, Connors J M. Primary paranasal sinus lymphoma: natural history and improved outcome with central nervous system chemoprophylaxis. Leuk Lymphoma 2005; 46: 1721–1727
   PubMed Web of Science ®Google Scholar
• Hill Q A, Owen R G. CNS prophylaxis in lymphoma: who to target and what therapy to use. Blood Rev 2006; 20: 319–332
   PubMed Web of Science ®Google Scholar
• Avilés A, Delgado S, Nambo M J, Neri N, Murillo E, Cleto S. Primary breast lymphoma: results of a controlled clinical trial. Oncology 2005; 69: 256–260
   PubMed Web of Science ®Google Scholar
• Gholam D, Bibeau F, El Weshi A, Bosq J, Ribrag V. Primary breast lymphoma. Leuk Lymphoma 2003; 44: 1173–1178
   PubMed Web of Science ®Google Scholar
• Wong W W, Schild S E, Halyard M Y, Schomberg P J. Primary non-Hodgkin lymphoma of the breast: the Mayo clinic experience. J Surg Oncol 2002; 80: 19–25, discussion 26
   PubMed Web of Science ®Google Scholar
• Ganjoo K, Advani R, Mariappan M R, McMillan A, Horning S. Non-Hodgkin lymphoma of the breast. Cancer 2007; 110: 25–30
   PubMed Web of Science ®Google Scholar
• Ryan G, Martinelli G, Kuper-Hommel M, Tsang R, Pruneri G, Yuen K, et al. International extranodal lymphoma study group. Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the international extranodal lymphoma study group. Ann Oncol 2008; 19: 233–241
   PubMed Web of Science ®Google Scholar
• van Besien K, Ha C S, Murphy S, McLaughlin P, Rodriguez A, Amin K, et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 1998; 91: 1178–1184
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008; 9: 105–116
   PubMed Web of Science ®Google Scholar
• Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M, et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma – a survey of 1693 patients treated in protocols of the German high-grade non-Hodgkin's lymphoma study group (DSHNHL). Ann Oncol 2007; 18: 149–157
   PubMed Web of Science ®Google Scholar
• Boehme V, Zeynalova S, Lengfelder E, Franke A, Reiser M, Steinhauer H, et al. CNS disease in elderly patients treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of CNS events in the RICOVER-60 trial of the German high-grade non-Hodgkin's lymphoma study group (DSHNHL). Blood 2007; 110, Abstract 519
   Google Scholar
• Chua S L, Seymour J F, Streater J, Wolf M M, Januszewicz E H, Prince H M. Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma. Leuk Lymphoma 2002; 43: 1783
   PubMed Web of Science ®Google Scholar
• Tomita N, Kodama F, Kanamori H, Motomura S, Ishigatsubo Y. Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-Hodgkin lymphoma. Cancer 2002; 95: 576–580
   PubMed Web of Science ®Google Scholar
• Arkenau H T, Chong G, Cunningham D, Watkins D, Agarwal R, Sirohi B, et al. The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma. Ann Oncol 2007; 18: 541–545
   PubMed Web of Science ®Google Scholar
• Tilly H, Lepage E, Coiffier B, Blanc M, Herbrech R, Bosly A, et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2003; 102: 4284–4289
   PubMed Web of Science ®Google Scholar
• George S L, Ochs J J, Mauer A M, Simone J V. The importance of an isolated central nervous system relapse in children with acute lymphoblastic leukemia. J Clin Oncol 1985; 3: 776–781
   PubMed Web of Science ®Google Scholar
• Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F, et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: societe francaise de greffe de Moelle Osseuse-therapie cellulaire. J Clin Oncol 2008; Apr 14, [Epub ahead of print]
   Google Scholar
• Soussain C, Suzan F, Hoang-Xuan K, Cassoux N, Levy V, Azar N, et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 2001; 19: 742–749
   PubMed Web of Science ®Google Scholar